MBIO - Mustang Bio reports initial data on MB-105 in prostate cancer

Mustang Bio (MBIO) presents one patient‘s experience on the Phase 1 trial of MB-105, a prostate stem cell antigen ((PSCA)) chimeric antigen receptor ((CAR)) T administered to patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC) at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat. In a 73-year-old male patient, treated with MB-105 and lymphodepletion (a standard CAR T pre-conditioning regimen) after failing eight prior therapies, MB-105 demonstrated a 94% reduction in prostate-specific antigen ((PSA)), near complete reduction of measurable soft tissue metastasis, and improvement in bone metastases on day 28.The therapy was associated with cytokine release syndrome, which was clinically managed with tocilizumab (anti-IL-6 receptor antibody), and hemorrhagic cystitis requiring transfusion which clinically resolved in 30 days. The Phase 1 trial will continue to enroll up to 33 patients. Its primary endpoints are to define safety and optimal dosing of PSCA CAR T cells in treating patients with PSCA-positive

For further details see:

Mustang Bio reports initial data on MB-105 in prostate cancer